Current Progress and Future With Glembatumumab Vedotin in TNBC

Inavolisib showed promise in treating patients with PIK3CA-mutated solid tumors, demonstrating favorable safety and disease control.

In season 3, episode 3 of Targeted Talks, William J. Gradishar, MD, discusses the latest version of the NCCN Clinical Practice Guideline for managing early-stage breast cancer.

Non-operative management showed promising results for patients with mismatch repair proficient locally advanced rectal cancer, preserving organs without compromising survival.

In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.

Combining endocrine therapy with the dual HER2 blockade of trastuzumab and pertuzumab and the CDK4/6 inhibitor ribociclib showed potential as a novel approach for patients with HR+/HER2+ breast cancer.

The ARANOTE trial confirmed radiographical PFS benefit to adding darolutamide to androgen deprivation therapy without docetaxel in the metastatic hormone-sensitive prostate cancer setting.